Abstract
Background: Rivaroxaban is widely used for stroke prevention in patients with atrial fibrillation, yet the safety of thrombolysis in anticoagulated patients is uncertain. Methods: We analyzed the characteristics, indications, and 30-day rates of stroke, mortality, and bleeding in patients who
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
